News

SpaceX, IBM and Boston Scientific fell to 52-week lows on Wednesday as Wall Street concerns and profit-taking sent the stocks lower.

Shareholders of Boston Scientific would probably like to forget the past six months even happened. The stock dropped 52.5% and now trades at $42.79. This was partly driven by its softer quarterly results and might have investors contemplating their next move.

With an upside potential of 62.55%, Boston Scientific Corporation (NYSE:BSX) is among the 12 Strong Buy Stocks with High Upside According to Analysts. On July 8, Needham analyst Mike Matson lowered the firm’s price target on Boston Scientific Corporation (NYSE:BSX) to $57 from $77 while maintaining a Buy rating on the shares. The adjustment followed management commentary […]

Boston Scientific recently initiated several voluntary Class II recalls of its CRE and CRE Pro Wireguided endoscopy devices worldwide due to potential sterile breaches in packaging, affecting tens of thousands of units across multiple size ranges. The recalls underscore the operational and regulatory risks inherent in Boston Scientific’s expanding minimally invasive device portfolio, especially as it integrates recent acquisitions and scales global distribution. We’ll now examine how these...

In the latest trading session, Boston Scientific (BSX) closed at $42.63, marking a -4.52% move from the previous day.

Intuitive Surgical heads into Q2 earnings with strong procedure momentum, da Vinci 5 adoption and expectations for another earnings beat despite margin pressures.

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.

Boston Scientific Corporation (NYSE:BSX) is one of the 10 Best Stocks to Buy in 2026 According to Billionaire D.E. Shaw. Boston Scientific Corporation (NYSE:BSX) is one of the largest medical device companies in America. Its shares are down by 56% over the past year and by 52% year-to-date. Jefferies was out with a devastating note […]

The average brokerage recommendation (ABR) for Boston Scientific (BSX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

If you hold shares in this medical device maker, you are already carrying the full weight of a sizable potential swing that the market is pricing for the year ahead.

Johnson & Johnson expects U.S. physicians to perform the first procedures with the device this summer as it starts a phased commercial rollout.

Steve Cohen, head of Point72 Asset Management, dumped tech stocks and bought this unloved healthcare company.

Generate an immediate income that you keep regardless, plus the opportunity to buy the stock cheaper should its price fall far enough.

Boston Scientific stock moves after clinical results and index changes Boston Scientific (BSX) has come into focus after promising clinical results coincided with multiple index removals and fresh analyst commentary on its Watchman device franchise and utilization trends. Shares recently moved higher, supported by the clinical update and reports of insider buying, even as analysts highlighted slower Watchman growth and trimmed their expectations. At the same time, Boston Scientific was...

Boston Scientific (BSX) closed at $44.6 in the latest trading session, marking a -1.2% move from the prior day.

Boston Scientific Corporation (NYSE:BSX) is one of the best stocks to invest in according to Two Sigma Advisors with huge upside potential. On June 24, Jefferies analyst Matthew Taylor cut his price target on Boston Scientific Corporation (NYSE:BSX) to $67 from $100, while keeping a Buy rating on the stock. The analyst stated that a […]

Boston Scientific stock has fallen 56.5% over the past year, yet the valuation checks still lean toward the shares looking cheap relative to fundamentals and recent news has put a fresh spotlight on whether that gap is justified. The 56.5% one year share price decline raises the question of whether Boston Scientific is being priced for a much weaker outlook than its long term potential would suggest. On one side, the US$1.5b investment in MiRus and option to acquire its TAVR business may...

JNJ's Q2 MedTech results will test whether cardiovascular, surgery and vision strength can offset ongoing China VBP headwinds and sustain growth.

Boston Scientific, Medtronic and Stryker were among the companies to ink deals to move into markets that are expanding quickly.

While a guidance cut has reset expectations, several core Boston Scientific franchises are accelerating. The Neuromodulation and Interventional Oncology businesses both posted organic sales growth of 15% last quarter. This internal momentum in high-value categories contrasts sharply with the new, more cautious company-wide outlook.

Boston Scientific is gearing up for earnings day, weighing a rocky stock run against Wall Street's stubbornly optimistic outlook.

Boston Scientific Corporation (NYSE:BSX) is one of the most promising future stocks to buy right now. Stifel cut the price target on Boston Scientific Corporation (NYSE:BSX) to $65 from $75 on June 25 and reaffirmed a Buy rating on the shares. The rating update came after the firm hosted five deep left atrial appendage closure […]

In the most recent trading session, Boston Scientific (BSX) closed at $42.68, indicating a -1.84% shift from the previous trading day.

Boston Scientific Corporation (NYSE:BSX) is one of the oversold tech stocks to buy now. On May 18, Boston Scientific invested $1.5 billion for a 34% equity stake in MiRus LLC, a company specializing in advanced biomaterials and medical implants. The deal includes an exclusive option for Boston Scientific to acquire MiRus’s proprietary TAVR system, which […]

Edwards Lifesciences is expected to introduce the new device to surgical heart valve customers this year in a “measured, targeted rollout,” one analyst said.

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.

Boston Scientific Corporation (NYSE:BSX) is one of the best low volatility stocks to buy under $50. BofA cut the price target on Boston Scientific Corporation (NYSE:BSX) to $61 from $68 on June 12 and maintained a Buy rating on the shares. It noted that the firm’s services team continues to highlight a lower utilization environment, […]

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 9.5% over the past six months while the S&P 500 was up 6.2%.

Boston Scientific Corporation (NYSE:BSX) is one of the Stocks Expected to Bounce Back According to Analysts. The stock has fallen more than 52% year-to-date, but the Street expects more than 65% upside from the current level. ​Recently, on June 16, TD Cowen analyst Josh Jennings maintained his Buy rating on Boston Scientific Corporation (NYSE:BSX) with […]